Heart Failure Outcomes
The SUMMIT trial (presented at AHA 2024, simultaneously published in NEJM) evaluated tirzepatide in 731 patients with obesity-related heart failure with preserved ejection fraction (HFpEF) over approximately 2 years. HFpEF is the most common form of heart failure (approximately 50% of all HF cases) and is strongly associated with obesity and T2D, with few proven pharmacological disease-modifying treatments. The SUMMIT results represent a significant advance for this condition.
Primary outcome: Tirzepatide significantly reduced the composite of worsening heart failure events (HF hospitalisation + urgent HF visit + cardiovascular death) by approximately 46% compared to placebo. Quality of life (Kansas City Cardiomyopathy Questionnaire) also improved significantly. An important caveat: cardiovascular death was numerically higher with tirzepatide (2.2% vs 1.4%) — not statistically significant and possibly due to chance with the trial’s size, but a finding that warrants attention in Phase 3 follow-up.
Mechanism (SUMMIT secondary analyses): A cardiac MRI substudy (JACC 2025) showed tirzepatide reduced left ventricular mass and paracardiac adipose tissue, paralleling weight loss — suggesting structural cardiac remodelling. A Nature Medicine 2025 secondary analysis (PMID 39551891) showed tirzepatide reduced circulatory volume-pressure overload, systemic inflammation, and markers of cardiovascular-kidney end-organ damage (troponin T, reduced C-reactive protein correlated with improved 6-minute walk distance).
Vault context — relevance to T2D: The SUMMIT trial enrolled patients with HFpEF and obesity regardless of T2D status — approximately 50-60% of HFpEF patients in clinical practice have T2D. For T2D patients who also have HFpEF (a common overlap), tirzepatide now has direct heart failure outcomes evidence in addition to its T2D and cardiovascular benefits. The ADA/EASD 2022 consensus noted SGLT2i were preferred for heart failure — SUMMIT now provides comparable HFpEF outcomes evidence for tirzepatide in the obesity-related HFpEF phenotype specifically, while semaglutide demonstrated similar findings in STEP-HFpEF.
Ontology Heart Failure Outcomes [evidence_from] Tirzepatide Heart Failure Outcomes [relates] Cardiovascular Risk Heart Failure Outcomes [relates] SURPASS-CVOT Heart Failure Outcomes [relates] ADA EASD 2022 Consensus Report
Numbers
| Outcome | Tirzepatide | Placebo | Effect |
|---|---|---|---|
| Worsening HF events (composite) | Lower | — | ~46% relative reduction |
| CV death | 2.2% | 1.4% | Numerically higher; NOT significant |
| LV mass (CMR) | Reduced | — | Paralleled weight loss |
| Paracardiac adipose (CMR) | Reduced | — | Significant |
| 6-min walk distance | Improved | — | Correlated with CRP reduction |
Practical Interpretation
- Who this applies to: T2D patients with obesity-related HFpEF — a very common overlap
- Implication: Tirzepatide now has outcomes evidence for HFpEF (obesity type), complementing SGLT2i evidence for HFrEF/HFpEF
- Caveat: Numerically higher CV death signal — not confirmed but watch future Phase 3 data
- Clinical positioning: For T2D + obesity + HFpEF: tirzepatide may be preferred over GLP-1 RA (per SUMMIT) and complements SGLT2i (per KDIGO/EASD recommendation)
Connections
- Tirzepatide — evidence_for (HFpEF outcomes benefit)
- Cardiovascular Risk — relates
- SURPASS-CVOT — relates (CV outcomes evidence)
- ADA EASD 2022 Consensus Report — relates (SGLT2i preferred for HF; SUMMIT adds tirzepatide evidence)